London Stock Exchange welcomes SourceBio International plc to AIM

London Stock Exchange today welcomes SourceBio International plc (‘SourceBio’ or the ‘Company’), a leading international provider of integrated state-of-the-art laboratory services and products, to celebrate the listing of the Company's public shares onto AIM, under the ticker "SBI".

SourceBio, employs approximately 235 employees across six sites globally, in the UK, Ireland and the USA with headquarters in Nottingham, UK. The Company provides services and products to clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. SourceBio operates with four core businesses areas:

•    Healthcare Diagnostics - histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland;
•    Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America;
•    Stability Storage - shelf life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA; and
•    Infectious Disease Testing - since May 2020, the Group has provided COVID-19 Antigen RT-PCR testing services. These services passed all of the auditing requirements of the NHS and the Department of Health and Social Care (DHSC) in April 2020. It is intended that this offering will potentially provide a broad range of infectious disease testing across the NHS, private healthcare and commercial sectors in the future.

The Directors believe that the Group is well positioned to capitalise on attractive market opportunities across all of its core business divisions.

The Company has successfully raised £35 million (before expenses) through a placing of new Ordinary Shares, to repay outstanding shareholder and bank loans and for general corporate expenses, including working capital and capital expenditure required in order to further scale-up the COVID-19 testing business. On Admission, the Company will have a market capitalisation of approximately £120m.

Jay LeCoque, Executive Chairman of SourceBio, said: “We are delighted by the strong support we’ve received from new institutional investors and our existing shareholders. Our IPO on AIM allows us to significantly increase our COVID-19 testing capacity, accelerate earnings growth in our core business and execute on potential M&A opportunities. It’s an exciting time for our business and we look forward to executing on our ambitious growth plans and delivering value to our shareholders.”

To find out more about SourceBio visit:  www.sourcebiointernational.com

Quick facts

Track
Market: AIM
Instrument market cap (£m)
93.47
Listing/Admission to trading
29 Oct 2020
Looking for new and recent issues?

More recent

London Stock Exchange Group welcomes City Giving Day celebrating volunteering and philanthropy in the City of London

City Giving Day is The Lord Mayor’s Appeal’s annual celebration of philanthropy and giving which provides City organisations with an opportunity to reflect on everything they do to support their local communities and charities.

Championed by successive Lord Mayors of the City of London, City Giving Day has gone from strength to strength with a record 500 companies taking part this yea

Learn more
London International Shipping Week 2021

London International Shipping Week 2021 (LISW21) is seen throughout the world as the ‘must attend’ international maritime event of the year. London is the historic centre of global trade and world shipping and stands at the heart of international commerce. Its long-standing maritime institutions have been servicing the global shipping industry for centuries and that role co

Learn more
57.28
London Stock Exchange welcomes LungLife AI

London Stock Exchange welcomes LungLife AI, Inc. to trading on AIM. In July 2021 LungLife successfully raised gross proceeds of £17 million and the Company’s market capitalisation on admission was £45 million with a free float of 50.6%. 

LungLife AI’s mission is to make a significant impact in the early detection of lung cancer. The Company is a develop

Learn more
33.56
London Stock Exchange welcomes Likewise Group plc to AIM

Likewise is a UK distributor of both domestic and commercial floorcoverings and matting. It is challenging the established competitors in the industry by providing access to a wide choice of flooring from multiple manufacturers across the globe at competitive prices for its customers. The Directors believe they have an opportunity to build a

Learn more